Status:
NOT_YET_RECRUITING
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Depression - Major Depressive Disorder
Cannabis Use Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized...
Eligibility Criteria
Inclusion
- Aged ≥ 18 years
- Resides in the United States
- Able to read and understand English and willing to provide informed consent/comply with the study protocol
- Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
- Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
- Current elevated anhedonia, as indicated by the PHQ-9
- Interest in receiving treatment for their cannabis use and/or depression
- Meet criteria for current MDD and CUD per the DSM-5
Exclusion
- History of a psychotic disorder or bipolar disorder type I/II
- Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
- Current psychotherapy engagement
- Changes in psychotropic medication within six weeks of the start of study
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2030
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06878859
Start Date
January 1 2026
End Date
March 1 2030
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114